Pablo J. Cagnoni, President and Global Head of R&D at Incyte Corp, filed a Form 4 on November 18, 2026, disclosing option exercises and open-market share sales that occurred on November 16, 2026, pursuant to a Rule 10b5-1 trading plan.
Key Highlights
- Four option tranches exercised: Cagnoni exercised employee stock options covering 455, 422, 926, and 839 shares at exercise prices of $61.18, $61.76, $64.25, and $71.93, respectively, all on November 16, 2026.
- Shares sold in two transactions: 877 shares were sold at $121.98 and 1,765 shares were sold at $120.46 on November 16, 2026.
- Remaining beneficial ownership: Following all reported transactions, Cagnoni directly beneficially owned 183,200 shares of common stock.
- RSU and PSU component: According to the filing, the 183,200 share total includes shares issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
- Rule 10b5-1 plan: The filing indicates the transactions were made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
- Remaining option holdings: After the exercises, Cagnoni held 3,641, 3,380, 18,505, and 16,788 options in the four respective tranches.
Incyte Corp Officer Reports Option Exercises and Share Sales Under 10b5-1 Plan
Pablo J. Cagnoni, identified in the filing as President and Global Head of R&D at Incyte Corp (NASDAQ:INCY), reported a series of transactions in the company's common stock on November 16, 2026. The Form 4 was filed on November 18, 2026, and indicates the transactions were executed under a Rule 10b5-1(c) trading plan.
In Table I, four acquisition entries reflect the exercise of employee stock options using transaction code "M." The shares acquired were 455 at $61.18, 422 at $61.76, 926 at $64.25, and 839 at $71.93 per share. Two subsequent dispositions, coded "S," show sales of 877 shares at $121.98 and 1,765 shares at $120.46. The filing notes that the final post-transaction holding of 183,200 shares includes shares issuable under previously reported restricted stock units and earned performance stock units that have not yet vested.
Table II details the corresponding reductions in derivative securities. The four option grants carry expiration dates of January 17, 2034, July 13, 2033, July 14, 2034, and January 16, 2035, respectively. Each grant vests in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years, as described in the filing's explanatory footnotes. The price of each derivative security at exercise is listed as $0.
What Was Disclosed
The filing reports that on November 16, 2026, Cagnoni exercised four tranches of employee stock options totaling 2,642 shares and sold a combined 2,642 shares in two open-market transactions, all under a Rule 10b5-1 plan, leaving a reported beneficial ownership of 183,200 shares.





Please wait processing your request...